Goldman Sachs Initiates Coverage of Bruker Corporation - Preferred Stock (BRKRP) with Sell Recommendation

On Dec. 9, 2025 Goldman Sachs initiated coverage of Bruker Corporation preferred stock (Nasdaq: BRKRP) with a Sell recommendation. As of Dec. 6, 2025 the average one‑year price target was $365.60—just 3.68% above the latest close of $352.63—with targets ranging from $280.10 to $606.66 and a projected annual non‑GAAP EPS of 2.01. Major holders include Aequim Alternative Investments (300k shares), D.E. Shaw (205k), Franklin Resources (200k), Advent Capital (113k) and Calamos (100k). GS’s Sell call, the modest consensus upside and the wide dispersion of analyst targets suggest limited near‑term upside and divergent views that could weigh on secondary-market sentiment for the preferred.

Analysis

Goldman Sachs initiated coverage of Bruker Corporation preferred stock (Nasdaq: BRKRP) on December 9, 2025 with a Sell recommendation, according to Fintel. As of December 6 the average one‑year price target stood at $365.60, representing a 3.68% premium to the latest close of $352.63, while individual analyst targets range widely from $280.10 to $606.66; Fintel also reports a projected annual non‑GAAP EPS of 2.01.

A Sell from GS alongside a modest consensus upside suggests Goldman sees downside or valuation risk not fully reflected in the average target; the $280–$606 dispersion indicates substantial analyst disagreement and potential for short‑term volatility. Sentiment outputs are mildly negative overall and strongly negative for BRKRP (per‑ticker score −0.6) with a market impact score of 0.28, implying the initiation could produce measurable but not systemic market movement.

Major institutional holders—Aequim Alternative Investments (300k shares), D.E. Shaw (205k), Franklin Resources (200k), Advent Capital (113k) and Calamos (100k)—represent meaningful positioning that could affect liquidity and price action. Investors should therefore treat upside as limited until GS publishes its full rationale or the company provides clarifying earnings/dividend commentary, and expect sensitivity to analyst revisions and institutional flow.

Key Decisions for Investors

• Reduce or hedge exposure to BRKRP given Goldman Sachs' Sell initiation and only ~3.7% consensus upside, particularly if your position is large
• Monitor the wide $280.10–$606.66 analyst target range and subsequent research notes for signs of increased volatility; size new positions conservatively and consider options hedges
• Track activity by major holders (Aequim, D.E. Shaw, Franklin, Advent, Calamos) and await Goldman Sachs' published rationale or company commentary before adding to positions